QQ客服 官方微博 反馈留言

	Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors
	Sun, Yongkun; Yang, Lin; Hao, Xuezhi; Liu, Yutao; Zhang, Jinwen; Ning, Zhiqiang; Shi, Yuankai
	2019
卷号	12期号:1页码:9
关键词	Advanced solid tumors Chiauranib Dose-escalation Pharmacokinetics Phase I study Safety
ISSN号	1756-8722
DOI	10.1186/s13045-018-0695-0
URL标识	查看原文
收录类别	SCIE ; PUBMED
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6345172
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Sun, Yongkun,Yang, Lin,Hao, Xuezhi,et al. Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors[J],2019,12(1):9.
APA	Sun, Yongkun.,Yang, Lin.,Hao, Xuezhi.,Liu, Yutao.,Zhang, Jinwen.,...&Shi, Yuankai.(2019).Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors.,12(1),9.
MLA	Sun, Yongkun,et al."Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors".12.1(2019):9.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。